| A Study of APG-3288 in Relapsed/Refractory Blood Cancers (NCT07424833) | Ascentage Pharma Group Inc. | 2026-08-01 |
| Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment (NCT07282093) | Ascentage Pharma Group Inc. | 2025-11-11 |
| APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST (NCT06687070) | Ascentage Pharma Group Inc. | 2024-12-17 |
| A Study of Olverembatinib in SDH-deficient GIST. (NCT06640361) | Ascentage Pharma Group Inc. | 2024-11-11 |
| A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. (NCT06182969) | Ascentage Pharma Group Inc. | 2024-08-09 |
| A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia (NCT06389292) | Ascentage Pharma Group Inc. | 2024-06-11 |
| A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. (NCT06319456) | Ascentage Pharma Group Inc. | 2024-04-07 |
| Study of Olverembatinib (HQP1351) in Patients With CP-CML (NCT06423911) | Ascentage Pharma Group Inc. | 2024-02-05 |
| Global Trial in APG2575 for Patients With CLL/SLL (NCT06104566) | Ascentage Pharma Group Inc. | 2023-12-20 |
| A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) (NCT06051409) | Ascentage Pharma Group Inc. | 2023-08-31 |
| A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918. (NCT05773586) | Ascentage Pharma Group Inc. | 2023-03-13 |
| APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors (NCT05701306) | Ascentage Pharma Group Inc. | 2023-02-28 |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas (NCT05415098) | Ascentage Pharma Group Inc. | 2022-09-30 |
| The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects (NCT05517616) | Ascentage Pharma Group Inc. | 2022-09-14 |
| APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05186012) | Ascentage Pharma Group Inc. | 2022-06-14 |
| A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors (NCT04893759) | Ascentage Pharma Group Inc. | 2022-01-06 |
| Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL (NCT05147467) | Ascentage Pharma Group Inc. | 2021-12-28 |
| A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer (NCT04946864) | Ascentage Pharma Group Inc. | 2021-08-13 |
| A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) (NCT04964518) | Ascentage Pharma Group Inc. | 2021-07-30 |
| A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL (NCT04496349) | Ascentage Pharma Group Inc. | 2021-07-12 |
| APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (NCT04260217) | Ascentage Pharma Group Inc. | 2021-05-30 |
| APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors (NCT04785196) | Ascentage Pharma Group Inc. | 2021-05-26 |
| APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma (NCT04674514) | Ascentage Pharma Group Inc. | 2021-04-13 |
| APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma (NCT04643405) | Ascentage Pharma Group Inc. | 2021-03-17 |
| A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy (NCT04354727) | Ascentage Pharma Group Inc. | 2020-12-15 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS (NCT04358393) | Ascentage Pharma Group Inc. | 2020-12-04 |
| Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (NCT04501120) | Ascentage Pharma Group Inc. | 2020-09-28 |
| Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer (NCT04210037) | Ascentage Pharma Group Inc. | 2020-08-20 |
| A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. (NCT04275518) | Ascentage Pharma Group Inc. | 2020-07-06 |
| A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B (NCT04568265) | Ascentage Pharma Group Inc. | 2020-06-03 |
| Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors (NCT04284488) | Ascentage Pharma Group Inc. | 2020-04-10 |
| Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL (NCT04215809) | Ascentage Pharma Group Inc. | 2020-03-02 |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL (NCT04260022) | Ascentage Pharma Group Inc. | 2020-01-09 |
| The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans (NCT04126707) | Ascentage Pharma Group Inc. | 2019-11-19 |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase (NCT04126681) | Ascentage Pharma Group Inc. | 2019-10-21 |
| A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients (NCT04001777) | Ascentage Pharma Group Inc. | 2019-07-04 |
| A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies (NCT03913949) | Ascentage Pharma Group Inc. | 2019-06-03 |
| A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation (NCT03883087) | Ascentage Pharma Group Inc. | 2019-04-08 |
| A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation (NCT03883100) | Ascentage Pharma Group Inc. | 2019-04-08 |
| Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia (NCT03882281) | Ascentage Pharma Group Inc. | 2019-03-25 |
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors (NCT03611868) | Ascentage Pharma Group Inc. | 2018-08-29 |
| APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies (NCT03537482) | Ascentage Pharma Group Inc. | 2018-08-07 |
| A Study of HQP1351 in Patients With GIST or Other Solid Tumors (NCT03594422) | Ascentage Pharma Group Inc. | 2018-07-11 |
| APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B (NCT03585322) | Ascentage Pharma Group Inc. | 2018-07-04 |
| APG-1252 in Patients With SCLC or Advanced Solid Tumors (NCT03387332) | Ascentage Pharma Group Inc. | 2017-12-01 |
| APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies (NCT03386526) | Ascentage Pharma Group Inc. | 2017-11-21 |